Tandem Diabetes Care | TNDM - Gross Profit On Sales


Tandem Diabetes Care reported $167.46M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Accuray USD 41.89M 7.42M Dec/2024
Align Technology USD 683.59M 44.39M Dec/2025
AtriCure USD 105.34M 4M Dec/2025
Baxter International USD 577M 373M Dec/2025
Becton, Dickinson and Co. USD 2.41B 1.72B Dec/2025
Boston Scientific USD 3.68B 136M Dec/2025
Cooper Companies USD 695.2M 44.4M Dec/2025
Dexcom USD 792.7M 61.3M Dec/2025
Edwards Lifesciences USD 1.23B 18.7M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Globus Medical USD 535.95M 49.28M Dec/2025
ICU Medical USD 202.98M 2.1M Dec/2025
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 568.6M 58.5M Dec/2025
Integra LifeSciences USD 217.1M 10.11M Dec/2025
Intuitive Surgical USD 1.9B 241.9M Dec/2025
J&J USD 16.6B 118M Dec/2025
Masimo USD 247.3M 16.7M Dec/2025
Medtronic USD 5.41B 27M Dec/2025
Merit Medical Systems USD 195.35M 8.94M Dec/2025
Orthofix International USD 153.28M 4.76M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Stryker USD 4.49B 633M Dec/2025
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.45M 144.2M Dec/2025
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025